Partial ileal bypass affords protection from onset of type 2 diabetes

Henry Buchwald, Danette M. Oien, Decel J. Schieber, John P. Bantle, John E. Connett

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Partial ileal bypass (PIB) in the National Institutes of Health–sponsored Program on the Surgical Control of the Hyperlipidemias (POSCH) randomized controlled trial was found to reduce plasma cholesterol, in particular low density lipoprotein cholesterol, with concomitant retardation of atherosclerotic cardiovascular disease and increased life expectancy. Glucagon-like peptide-1, related to amelioration of type 2 diabetes, is increased over 5-fold after PIB. We hypothesized that PIB, in addition to its action on cholesterol metabolism, may also prevent type 2 diabetes. Methods We surveyed by telephone inquiry of former POSCH patients the 30+year posttrial incidence of type 2 diabetes or prediabetes, the presence of which was a trial exclusion criteria. We were able to contact 17.4% (n = 838) of the original POSCH population. Results Of 66 control responders, 17 contracted type 2 diabetes (25.8%); of 80 PIB responders, 8 contracted type 2 diabetes (10%). The difference between groups was significant (P = .015 by Fisher exact test) with an odds ratio of .320 for the PIB group and an over 2-fold (2.6) increase in the incidence of type 2 diabetes in the controls. Including borderline type 2 diabetes (prediabetic) patients, these values were 22 of 66 controls (33.3%) and 10 of 80 PIB patients (12.5%), with an odds ratio of .286 and a P<.004, and again an over 2-fold (2.7) increase in the incidence of type 2 diabetes in the control patients. Conclusion PIB appears to afford partial protection from the onset of type 2 diabetes for over 30 years.

Original languageEnglish (US)
Pages (from-to)45-51
Number of pages7
JournalSurgery for Obesity and Related Diseases
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Type 2 Diabetes Mellitus
Hyperlipidemias
Incidence
Odds Ratio
Cholesterol
Prediabetic State
Glucagon-Like Peptide 1
Life Expectancy
Telephone
LDL Cholesterol
Cardiovascular Diseases
Randomized Controlled Trials
Population

Keywords

  • 4 partial ileal bypass
  • POSCH
  • Type 2 diabetes

Cite this

Partial ileal bypass affords protection from onset of type 2 diabetes. / Buchwald, Henry; Oien, Danette M.; Schieber, Decel J.; Bantle, John P.; Connett, John E.

In: Surgery for Obesity and Related Diseases, Vol. 13, No. 1, 01.01.2017, p. 45-51.

Research output: Contribution to journalArticle

@article{df8d7053b7f74a94965b6cd5e38dfe96,
title = "Partial ileal bypass affords protection from onset of type 2 diabetes",
abstract = "Background Partial ileal bypass (PIB) in the National Institutes of Health–sponsored Program on the Surgical Control of the Hyperlipidemias (POSCH) randomized controlled trial was found to reduce plasma cholesterol, in particular low density lipoprotein cholesterol, with concomitant retardation of atherosclerotic cardiovascular disease and increased life expectancy. Glucagon-like peptide-1, related to amelioration of type 2 diabetes, is increased over 5-fold after PIB. We hypothesized that PIB, in addition to its action on cholesterol metabolism, may also prevent type 2 diabetes. Methods We surveyed by telephone inquiry of former POSCH patients the 30+year posttrial incidence of type 2 diabetes or prediabetes, the presence of which was a trial exclusion criteria. We were able to contact 17.4{\%} (n = 838) of the original POSCH population. Results Of 66 control responders, 17 contracted type 2 diabetes (25.8{\%}); of 80 PIB responders, 8 contracted type 2 diabetes (10{\%}). The difference between groups was significant (P = .015 by Fisher exact test) with an odds ratio of .320 for the PIB group and an over 2-fold (2.6) increase in the incidence of type 2 diabetes in the controls. Including borderline type 2 diabetes (prediabetic) patients, these values were 22 of 66 controls (33.3{\%}) and 10 of 80 PIB patients (12.5{\%}), with an odds ratio of .286 and a P<.004, and again an over 2-fold (2.7) increase in the incidence of type 2 diabetes in the control patients. Conclusion PIB appears to afford partial protection from the onset of type 2 diabetes for over 30 years.",
keywords = "4 partial ileal bypass, POSCH, Type 2 diabetes",
author = "Henry Buchwald and Oien, {Danette M.} and Schieber, {Decel J.} and Bantle, {John P.} and Connett, {John E.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.soard.2016.01.025",
language = "English (US)",
volume = "13",
pages = "45--51",
journal = "Surgery for Obesity and Related Diseases",
issn = "1550-7289",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Partial ileal bypass affords protection from onset of type 2 diabetes

AU - Buchwald, Henry

AU - Oien, Danette M.

AU - Schieber, Decel J.

AU - Bantle, John P.

AU - Connett, John E.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background Partial ileal bypass (PIB) in the National Institutes of Health–sponsored Program on the Surgical Control of the Hyperlipidemias (POSCH) randomized controlled trial was found to reduce plasma cholesterol, in particular low density lipoprotein cholesterol, with concomitant retardation of atherosclerotic cardiovascular disease and increased life expectancy. Glucagon-like peptide-1, related to amelioration of type 2 diabetes, is increased over 5-fold after PIB. We hypothesized that PIB, in addition to its action on cholesterol metabolism, may also prevent type 2 diabetes. Methods We surveyed by telephone inquiry of former POSCH patients the 30+year posttrial incidence of type 2 diabetes or prediabetes, the presence of which was a trial exclusion criteria. We were able to contact 17.4% (n = 838) of the original POSCH population. Results Of 66 control responders, 17 contracted type 2 diabetes (25.8%); of 80 PIB responders, 8 contracted type 2 diabetes (10%). The difference between groups was significant (P = .015 by Fisher exact test) with an odds ratio of .320 for the PIB group and an over 2-fold (2.6) increase in the incidence of type 2 diabetes in the controls. Including borderline type 2 diabetes (prediabetic) patients, these values were 22 of 66 controls (33.3%) and 10 of 80 PIB patients (12.5%), with an odds ratio of .286 and a P<.004, and again an over 2-fold (2.7) increase in the incidence of type 2 diabetes in the control patients. Conclusion PIB appears to afford partial protection from the onset of type 2 diabetes for over 30 years.

AB - Background Partial ileal bypass (PIB) in the National Institutes of Health–sponsored Program on the Surgical Control of the Hyperlipidemias (POSCH) randomized controlled trial was found to reduce plasma cholesterol, in particular low density lipoprotein cholesterol, with concomitant retardation of atherosclerotic cardiovascular disease and increased life expectancy. Glucagon-like peptide-1, related to amelioration of type 2 diabetes, is increased over 5-fold after PIB. We hypothesized that PIB, in addition to its action on cholesterol metabolism, may also prevent type 2 diabetes. Methods We surveyed by telephone inquiry of former POSCH patients the 30+year posttrial incidence of type 2 diabetes or prediabetes, the presence of which was a trial exclusion criteria. We were able to contact 17.4% (n = 838) of the original POSCH population. Results Of 66 control responders, 17 contracted type 2 diabetes (25.8%); of 80 PIB responders, 8 contracted type 2 diabetes (10%). The difference between groups was significant (P = .015 by Fisher exact test) with an odds ratio of .320 for the PIB group and an over 2-fold (2.6) increase in the incidence of type 2 diabetes in the controls. Including borderline type 2 diabetes (prediabetic) patients, these values were 22 of 66 controls (33.3%) and 10 of 80 PIB patients (12.5%), with an odds ratio of .286 and a P<.004, and again an over 2-fold (2.7) increase in the incidence of type 2 diabetes in the control patients. Conclusion PIB appears to afford partial protection from the onset of type 2 diabetes for over 30 years.

KW - 4 partial ileal bypass

KW - POSCH

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84973910979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973910979&partnerID=8YFLogxK

U2 - 10.1016/j.soard.2016.01.025

DO - 10.1016/j.soard.2016.01.025

M3 - Article

C2 - 27262236

AN - SCOPUS:84973910979

VL - 13

SP - 45

EP - 51

JO - Surgery for Obesity and Related Diseases

JF - Surgery for Obesity and Related Diseases

SN - 1550-7289

IS - 1

ER -